Evaluation of the risk of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors with cultured intestinal stem cells originated from crypts in humans and monkeys

Barker, 2014, Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration, Nat. Rev. Mol. Cell Biol., 15, 19, 10.1038/nrm3721 Belair, 2020, Human ileal organoid model recapitulates clinical incidence of diarrhea associated with small molecule drugs, Toxicol. in Vitro, 68, 10.1016/j.tiv.2020.104928 Boonekamp, 2020, Intestinal organoids as tools for enriching and studying specific and rare cell types: advances and future directions, J. Mol. Cell Biol., 12, 562, 10.1093/jmcb/mjaa034 Cross, 2014, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer, Cancer Discov., 4, 1046, 10.1158/2159-8290.CD-14-0337 Davis, 2011, Comprehensive analysis of kinase inhibitor selectivity, Nat. Biotechnol., 29, 1046, 10.1038/nbt.1990 Duan, 2019, Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea, JCI Insight, 4, 10.1172/jci.insight.126444 Friedlaender, 2022, EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment, Nat. Rev. Clin. Oncol., 19, 51, 10.1038/s41571-021-00558-1 Geyer, 2006, Lapatinib plus Capecitabine for HER2-positive advanced breast Cancer, N. Engl. J. Med., 355, 2733, 10.1056/NEJMoa064320 Harada, 2021, Calcium-activated chloride channel is involved in the onset of diarrhea triggered by EGFR tyrosine kinase inhibitor treatment in rats, Biomed. Pharmacother., 141, 10.1016/j.biopha.2021.111860 Hirsh, 2014, Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors, Curr. Oncol., 21, 329, 10.3747/co.21.2241 Hynes, 2005, ERBB receptors and cancer: the complexity of targeted inhibitors, Nat. Rev. Cancer, 5, 341, 10.1038/nrc1609 Johnston, 2009, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer, J. Clin. Oncol., 27, 5538, 10.1200/JCO.2009.23.3734 Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 352, 786, 10.1056/NEJMoa044238 Li, 2008, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene, 27, 4702, 10.1038/onc.2008.109 Matsui, 2021, Human organoids for predictive toxicology research and drug development, Front. Genet., 12, 10.3389/fgene.2021.767621 Michiba, 2021, Characterization of the human intestinal drug transport with Ussing chamber system incorporating freshly isolated human jejunum, Drug Metab. Dispos., 49, 84, 10.1124/dmd.120.000138 Michiba, 2022, Usefulness of human Jejunal spheroid-derived differentiated intestinal epithelial cells for the prediction of intestinal drug absorption in humans, Drug Metab. Dispos., 50, 204, 10.1124/dmd.121.000796 Miller, 2012, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-lung 1): a phase 2b/3 randomised trial, Lancet Oncol., 13, 528, 10.1016/S1470-2045(12)70087-6 Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol., 11, 121, 10.1016/S1470-2045(09)70364-X Miyoshi, 2013, In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture, Nat. Protoc., 8, 2471, 10.1038/nprot.2013.153 Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N. Engl. J. Med., 361, 947, 10.1056/NEJMoa0810699 Mok, 2017, Osimertinib or platinum-Pemetrexed in EGFR T790M-positive lung cancer, N. Engl. J. Med., 376, 629, 10.1056/NEJMoa1612674 Nam, 2011, Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer, Cancer Lett., 302, 155, 10.1016/j.canlet.2011.01.010 Okajima, 2021, A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata lung Cancer treatment group 1401), Transl. Lung Cancer Res., 10, 252, 10.21037/tlcr-20-649 Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med., 2 Park, 2016, Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-lung 7): a phase 2B, open-label, randomised controlled trial, Lancet Oncol., 17, 577, 10.1016/S1470-2045(16)30033-X Park, 2018, A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial, Int. J. Cancer, 143, 3240, 10.1002/ijc.31651 Peters, 2019, Human 3D gastrointestinal microtissue barrier function as a predictor of drug-induced diarrhea, Toxicol. Sci., 168, 3, 10.1093/toxsci/kfy268 Peters, 2020, Developing in vitro assays to transform gastrointestinal safety assessment: potential for microphysiological systems, Lab Chip, 20, 1177, 10.1039/C9LC01107B Robichaux, 2018, Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer, Nat. Med., 24, 638, 10.1038/s41591-018-0007-9 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol., 13, 239, 10.1016/S1470-2045(11)70393-X Sato, 2009, Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche, Nature, 459, 262, 10.1038/nature07935 Sato, 2011, Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts, Nature, 469, 415, 10.1038/nature09637 Sequist, 2013, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J. Clin. Oncol., 31, 3327, 10.1200/JCO.2012.44.2806 Tao, 2021, Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management, Toxicol. Res., 10, 476, 10.1093/toxres/tfab026 Thress, 2015, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat. Med., 21, 560, 10.1038/nm.3854 VanDussen, 2015, Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays, Gut, 64, 911, 10.1136/gutjnl-2013-306651 Wu, 2017, Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial, Lancet Oncol., 18, 1454, 10.1016/S1470-2045(17)30608-3 Yang, 2013, Diarrhea associated with afatinib: an oral ErbB family blocker, Expert. Rev. Anticancer. Ther., 13, 729, 10.1586/era.13.31 Yarden, 2001, Untangling the ErbB signalling network, Nat. Rev. Mol. Cell Biol., 2, 127, 10.1038/35052073 Zhai, 2020, Insight into the therapeutic selectivity of the irreversible EGFR tyrosine kinase inhibitor Osimertinib through enzyme kinetic studies, Biochemistry, 59, 1428, 10.1021/acs.biochem.0c00104